Biomark Diagnostics Inc. (FRA:20B)
Germany · Delayed Price · Currency is EUR 0.2760
0.00 (0.00%)
At close: Sep 15, 2026
Biomark Diagnostics Cash Flow Statement
Financials in millions CAD. Fiscal year is April - March.
Millions CAD. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | -1.43 | -1.48 | -1.93 | -1.43 | -1.84 | -1.45 |
Depreciation & Amortization | 0.38 | 0.38 | 0.4 | 0.39 | 0.39 | 0.18 |
Stock-Based Compensation | 0.04 | 0.04 | 0.37 | 0.08 | 0.33 | - |
Other Operating Activities | 0.07 | 0.06 | 0.06 | 0.06 | 0.07 | 0.03 |
Change in Accounts Receivable | 0.12 | 0.11 | -0.12 | -0.01 | 0.05 | -0.05 |
Change in Accounts Payable | -0.21 | -0.17 | 0.12 | -0.08 | 0.09 | 0.11 |
Change in Other Net Operating Assets | -0.03 | -0.04 | -0 | - | - | -0.02 |
Operating Cash Flow | -1.06 | -1.09 | -1.09 | -0.98 | -0.91 | -1.2 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Capital Expenditures | -0 | -0 | -0 | -0 | -0.01 | -0.06 |
Investment in Securities | 1.82 | -0.39 | - | - | - | - |
Investing Cash Flow | 1.82 | -0.4 | -0 | -0 | -0.01 | -0.06 |
Financing Activities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Short-Term Debt Issued | - | 0.36 | 0.38 | 0.36 | 0.44 | 0.51 |
Total Debt Issued | 0.36 | 0.36 | 0.38 | 0.36 | 0.44 | 0.51 |
Short-Term Debt Repaid | - | -0.33 | -0.15 | -0.77 | -0.45 | -0.33 |
Long-Term Debt Repaid | - | -0.43 | -0.41 | -0.41 | -0.38 | -0.31 |
Lease Payments | -0.44 | -0.43 | -0.41 | -0.41 | -0.38 | -0.31 |
Total Debt Repaid | -0.76 | -0.76 | -0.57 | -1.18 | -0.83 | -0.64 |
Net Debt Issued (Repaid) | -0.4 | -0.4 | -0.19 | -0.82 | -0.39 | -0.13 |
Issuance of Common Stock | 0.16 | 0.02 | 3.61 | 1.89 | 1 | 0.9 |
Financing Cash Flow | -0.24 | -0.38 | 3.42 | 1.07 | 0.61 | 0.77 |
Net Cash Flow
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Cash Flow | 0.52 | -1.86 | 2.33 | 0.08 | -0.31 | -0.49 |
Free Cash Flow
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -1.07 | -1.09 | -1.1 | -0.99 | -0.92 | -1.26 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | -3833.67% | -1828.20% | -711.12% | -604.65% | -599.20% | -2875.13% |
Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
Levered Free Cash Flow | -0.61 | -0.77 | -0.55 | -0.71 | -0.36 | -0.66 |
Unlevered Free Cash Flow | -0.56 | -0.73 | -0.51 | -0.67 | -0.29 | -0.64 |
Free Cash Flow After Leases | -1.5 | -1.53 | -1.51 | -1.39 | -1.3 | -1.57 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash Interest Paid | 0.06 | 0.06 | 0.06 | 0.06 | 0.07 | 0.03 |
Change in Working Capital | -0.13 | -0.1 | 0 | -0.09 | 0.14 | 0.04 |